Syndax Pharmaceuticals, Inc. (SNDX) Return on equity 2016–2025
Syndax Pharmaceuticals, Inc. (SNDX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-441.6%FY2025 · since FY2016: -52.9% → -441.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -441.6% | -330.9 pp |
| FY2024 | -110.6% | -72.9 pp |
| FY2023 | -37.8% | -5.8 pp |
| FY2022 | -31.9% | -38.0 pp |
| FY2021 | 6.1% | +35.1 pp |
| FY2020 | -29.0% | +148.4 pp |
| FY2019 | -177.4% | -37.9 pp |
| FY2018 | -139.4% | -81.1 pp |
| FY2017 | -58.3% | -5.4 pp |
| FY2016 | -52.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice